Compare American Financial Group Inc (AFG) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Amphastar Pharmaceuticals Inc — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.93B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: American Financial Group Inc is far larger — about 13.8× Amphastar Pharmaceuticals Inc's market cap, and American Financial Group Inc pays a 2.45% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AFG | AMPH | |
|---|---|---|
Market Cap | $11.93B | $863.95M |
Sector | Financials | Health |
52-Week High | $148.71 | $30.81 |
52-Week Low | $124.18 | $16.87 |
Enterprise Value | $12.31B | $1.26B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $145.59, down 0.78% on the day, with strong technical momentum indicated by bullish moving averages. The company reported solid Q2 2026 earnings of $2.82 per share, beating estimates by 21.6%, driven by record property and casualty operating income. Recent news highlights strong underwriting margins and premium growth, while institutional activity shows mixed positioning with some funds increasing stakes and others reducing holdings.
AFG presents a compelling investment case with a reasonable P/E of 12.73 and strong ROE of 20.41%, supported by consistent dividend payments. The consensus price target of $159.00 suggests 9.2% upside potential. Key risks include competitive pressures in insurance markets and potential margin compression. Analyst sentiment is cautiously optimistic with 41% buy ratings, though the majority maintain hold recommendations awaiting clearer growth catalysts.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
